Regulation and interactions in the activation of cell-associated plasminogen
- 1 November 2004
- journal article
- review article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 61 (22) , 2840-2858
- https://doi.org/10.1007/s00018-004-4230-9
Abstract
The main components in plasminogen activation include plasminogen, tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), urokinase plasminogen activator receptor (uPAR), and plasminogen activator inhibitors-1 and −2 (PAI-1, PAI-2). These components are subject to extensive regulation and interactions with for example, pericellular adhesion molecules. Although uPA and tPA are quite similar in structure and have common inhibitors and physiological substrates, their physiological roles are distinct. Traditionally, the role of tPA has been in fibrinolysis and that of uPA in cell migration, especially in cancer cells. Recently several targets for tPA/plasmin have been found in neuronal tissues. The functional role of the PAIs is no longer simply to inhibit overexpressed plasminogen activators, and PAI-2 has an unidentified role in the regulation of cell death.Keywords
This publication has 64 references indexed in Scilit:
- Psychische Belastung und Psychosomatischer Behandlungswunsch von Patienten mit Pulmonaler HypertoniePPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie, 2014
- Identification of a New Intronic BMPR2-Mutation and Early Diagnosis of Heritable Pulmonary Arterial Hypertension in a Large Family with Mean Clinical Follow-Up of 12 YearsPLOS ONE, 2014
- Anticoagulation and Survival in Pulmonary Arterial HypertensionCirculation, 2014
- The Combination of Exercise and Respiratory Training Improves Respiratory Muscle Function in Pulmonary HypertensionLung, 2013
- Riociguat for the Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2013
- Exercise training in pulmonary arterial hypertension associated with connective tissue diseasesArthritis Research & Therapy, 2012
- Safety and efficacy of exercise training in various forms of pulmonary hypertensionEuropean Respiratory Journal, 2012
- Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutationsRespiratory Research, 2011
- Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial HypertensionAnnals of Internal Medicine, 2008
- Mutations of the TGF-β type II receptorBMPR2 in pulmonary arterial hypertensionHuman Mutation, 2006